Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575037 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
A Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT05575037: Active Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease, sponsored by Brigham and Women's Hospital.
NCT05575037 is a Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05575037, a Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
Primary Outcome
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What the registry record for NCT05575037 still lists
NCT05575037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (83% lower).
The record links to 4 conditions, with Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05575037 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05575037 about?
NCT05575037 is a clinical study titled "Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease". The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
What is the current status of trial NCT05575037?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-08-01. Estimated completion is 2026-04-30.
What conditions does trial NCT05575037 study?
This clinical trial studies the following conditions: Nasal Polyps, Aspirin-exacerbated Respiratory Disease, Asthma, Aspirin-Induced, Aspirin-Sensitive Asthma With Nasal Polyps.
What interventions are being tested in trial NCT05575037?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05575037?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05575037 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Dupixent Study for Alternate Administration
ACTIVE NOT RECRUITING · Phase 4
-
Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
COMPLETED · Phase 4
-
The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA
COMPLETED · NA
-
Qualitative Analysis of Subject Experience of Nasal Polyps
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI